The purpose of this study is to assess the long-term safety of vedolizumab versus other
biologic agents in participants with Ulcerative Colitis (UC) or Crohn's Disease (CD).

This study will evaluate the safety and efficacy of Relamorelin compared to placebo in
patients with diabetic gastroparesis. Patients will report daily severity scores of their
diabetic gastroparesis symptoms.

Primary Objective:

The primary objective of this trial is to compare the clinical efficacy of BI 695501 with
EU-approved Humira® in patients with active Crohn's disease (CD).

Secondary Objectives:

The secondary objectives of this trial are to compare the efficacy and safety of BI 695501
with EU-approved Humira® across the induction and maintenance phases.